Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes

Journal of Immunology

Volumn 192, Issue 2, 2014, Pages 763-770

  Maier, Nolan K ^a   Crown, Devorah ^a   Liu, Jie ^b   Leppla, Stephen H ^a   Moayeri, Mahtab ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTHRAX LETHAL TOXIN; ANTHRAX TOXIN; ARSENIC TRIOXIDE; ARSENITE SODIUM; FLAGELLIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NIGERICIN; NITRIC OXIDE; NLR FAMILY APOPTOSIS INHIBITORY PROTEIN 5; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR LEUCINE RICH REPEAT PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR LEUCINE RICH REPEAT PROTEIN 3; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; MACROPHAGE; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, BACTERIAL; APOPTOSIS REGULATORY PROTEINS; ARSENICALS; ARSENITES; BACTERIAL TOXINS; CALCIUM-BINDING PROTEINS; CARRIER PROTEINS; CASPASE 1; CELL DEATH; CELL LINE; FLAGELLIN; IMMUNITY, INNATE; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, INBRED BALB C; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; NEUTROPHILS; NIGERICIN; NITROGEN OXIDES; NUCLEAR PROTEINS; OXIDES; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SODIUM COMPOUNDS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84892770596     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301434     Document Type: Article

References (55)

1. Martinon, F., A. Mayor, and J. Tschopp. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27: 229-265.
2. Lamkanfi, M., and V. M. Dixit. 2012. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 28: 137-161.
3. Hellmich, K. A., J. L. Levinsohn, R. Fattah, Z. L. Newman, N. Maier, I. Sastalla, S. Liu, S. H. Leppla, and M. Moayeri. 2012. Anthrax lethal factor cleaves mouse Nlrp1b in both toxin-sensitive and toxin-resistant macrophages. PLoS ONE 7: e49741.
4. Levinsohn, J. L., Z. L. Newman, K. A. Hellmich, R. Fattah, M. A. Getz, S. Liu, I. Sastalla, S. H. Leppla, and M. Moayeri. 2012. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog. 8: e1002638.
5. Kofoed, E. M., and R. E. Vance. 2011. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477: 592-595.
6. Zhao, Y., J. Yang, J. Shi, Y.-N. Gong, Q. Lu, H. Xu, L. Liu, and F. Shao. 2011. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477: 596-600.
7. Franchi, L., R. Muñoz-Planillo, and G. Núñez. 2012. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13: 325-332.
8. Hoffman, H. M., and A. A. Wanderer. 2010. Inflammasome and IL-1b-mediated disorders. Curr. Allergy Asthma Rep. 10: 229-235.
9. Zitvogel, L., O. Kepp, L. Galluzzi, and G. Kroemer. 2012. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13: 343-351.
10. Emadi, A., and S. D. Gore. 2010. Arsenic trioxide: an old drug rediscovered. Blood Rev. 24: 191-199.
11. Martin, W. J., M. Walton, and J. Harper. 2009. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum. 60: 281-289.
12. Park, S., and S. H. Leppla. 2000. Optimized production and purification of Bacillus anthracis lethal factor. Protein Expr. Purif. 18: 293-302. (Pubitemid 30213446)
13. von Moltke, J., N. J. Trinidad, M. Moayeri, A. F. Kintzer, S. B. Wang, N. van Rooijen, C. R. Brown, B. A. Krantz, S. H. Leppla, K. Gronert, and R. E. Vance. 2012. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490: 107-111.
14. Newman, Z. L., N. Sirianni, C. Mawhinney, M. S. Lee, S. H. Leppla, M. Moayeri, and L. M. Johansen. 2011. Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome. Antimicrob. Agents Chemother. 55: 1028-1035.
15. Meissner, F., K. Molawi, and A. Zychlinsky. 2008. Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat. Immunol. 9: 866-872.
16. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737. (Pubitemid 28243347)
17. Vitale, G., L. Bernardi, G. Napolitani, M. Mock, and C. Montecucco. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352: 739-745. (Pubitemid 32015030)
18. Boyden, E. D., and W. F. Dietrich. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38: 240-244. (Pubitemid 43177241)
19. Wickliffe, K. E., S. H. Leppla, and M. Moayeri. 2008. Anthrax lethal toxininduced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome. Cell. Microbiol. 10: 332-343.
20. Levin, T. C., K. E. Wickliffe, S. H. Leppla, and M. Moayeri. 2008. Heat shock inhibits caspase-1 activity while also preventing its inflammasome- mediated activation by anthrax lethal toxin. Cell. Microbiol. 10: 2434-2446.
21. Bhagat, L., V. P. Singh, R. K. Dawra, and A. K. Saluja. 2008. Sodium arsenite induces heat shock protein 70 expression and protects against secretagogueinduced trypsinogen and NF-kB activation. J. Cell. Physiol. 215: 37-46. (Pubitemid 351363189)
22. 231 cells. Life Sci. 77: 2783-2793. (Pubitemid 41297864)
23. Muehlbauer, S. M., H. Lima, Jr., D. L. Goldman, L. S. Jacobson, J. Rivera, M. F. Goldberg, M. A. Palladino, A. Casadevall, and J. Brojatsch. 2010. Proteasome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin. Am. J. Pathol. 177: 735-743.
24. Flora, S. J. S. 2011. Arsenic-induced oxidative stress and its reversibility. Free Radic. Biol. Med. 51: 257-281.
25. 3. Trends Mol. Med. 18: 36-42.
26. Lo, Y.-H., Y.-W. Huang, Y.-H. Wu, C.-S. Tsai, Y.-C. Lin, S.-T. Mo, W.-C. Kuo, Y.-T. Chuang, S.-T. Jiang, H.-M. Shih, and M.-Z. Lai. 2013. Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human. Blood 121: 3185-3194.
27. Newman, Z. L., M. P. Printz, S. Liu, D. Crown, L. Breen, S. Miller-Randolph, P. Flodman, S. H. Leppla, and M. Moayeri. 2010. Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1. PLoS Pathog. 6: e1000906.
28. Dinarello, C. A. 2011. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur. J. Immunol. 41: 1203-1217.
29. Waxman, S., and K. C. Anderson. 2001. History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl. 2): 3-10. (Pubitemid 32405843)
30. Doyle, D. 2009. Notoriety to respectability: a short history of arsenic prior to its present day use in haematology. Br. J. Haematol. 145: 309-317.
31. Zhu, J., Z. Chen, V. Lallemand-Breitenbach, and H. de Thé. 2002. How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2: 705-713. (Pubitemid 37328921)
32. Aronson, S. M. 1994. Arsenic and old myths. R. I. Med. 77: 233-234.
33. Kapahi, P., T. Takahashi, G. Natoli, S. R. Adams, Y. Chen, R. Y. Tsien, and M. Karin. 2000. Inhibition of NF-kB activation by arsenite through reaction with a critical cysteine in the activation loop of IkB kinase. J. Biol. Chem. 275: 36062-36066.
34. Roussel, R. R., and A. Barchowsky. 2000. Arsenic inhibits NF-kB-mediated gene transcription by blocking IkB kinase activity and IkBα phosphorylation and degradation. Arch. Biochem. Biophys. 377: 204-212. (Pubitemid 30257306)
35. Lu, J., E.-H. Chew, and A. Holmgren. 2007. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA 104: 12288-12293. (Pubitemid 47206130)
36. Styblo, M., S. V. Serves, W. R. Cullen, and D. J. Thomas. 1997. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 10: 27-33. (Pubitemid 27044904)
37. Martinon, F. 2010. Signaling by ROS drives inflammasome activation. Eur. J. Immunol. 40: 616-619.
38. Bauernfeind, F., E. Bartok, A. Rieger, L. Franchi, G. Núñez, and V. Hornung. 2011. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 187: 613-617.
39. Gross, O., C. J. Thomas, G. Guarda, and J. Tschopp. 2011. The inflammasome: an integrated view. Immunol. Rev. 243: 136-151.
40. Rubartelli, A. 2012. Redox control of NLRP3 inflammasome activation in health and disease. J. Leukoc. Biol. 92: 951-958.
41. Lengfelder, E., W.-K. Hofmann, and D. Nowak. 2012. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 26: 433-442.
42. Röllig, C., and T. Illmer. 2009. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat. Rev. 35: 425-430.
43. Wei, W., F. Zhou, Y. Zhang, L. Guo, H. Shi, and J. Hou. 2012. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes. Leuk. Res. 36: 715-719.
44. Carney, D. A. 2008. Arsenic trioxide mechanisms of action: looking beyond acute promyelocytic leukemia. Leuk. Lymphoma 49: 1846-1851.
45. Lust, J. A., and K. A. Donovan. 1999. The role of interleukin-1b in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. North Am. 13: 1117-1125. (Pubitemid 30017389)
46. Dunn, J. H., L. Z. Ellis, and M. Fujita. 2012. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 314: 24-33.
47. Goldberg, J. E., and K. L. Schwertfeger. 2010. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 11: 1133-1146.
48. Dinarello, C. A. 2010. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29: 317-329.
49. López-Castejón, G., and P. Pelegrín. 2012. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin. Investig. Drugs 21: 995-1007.
50. Bobé, P., D. Bonardelle, K. Benihoud, P. Opolon, and M. K. Chelbi-Alix. 2006. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 108: 3967-3975. (Pubitemid 44913262)
51. Shen, L., F. Gong, W. Tian, W. Li, F. Zhang, J. Qian, A. Sun, Y. Zou, W. Yang, and J. Ge. 2013. Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model. Biomed. Res. Int. 2013: 937936.
52. Singer, M., G. Trugnan, and M. K. Chelbi-Alix. 2011. Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-kB down-regulation and caspase-3 activation. Innate Immun 17: 365-374.
53. Xu, Z. P., J. M. Huo, Y. L. Sang, J. Kang, and X. Li. 2012. Effects of arsenic trioxide (As2O3) on airway remodeling in a murine model of bronchial asthma. Can. J. Physiol. Pharmacol. 90: 1576-1584.
54. Kingsbury, S. R., P. G. Conaghan, and M. F. McDermott. 2011. The role of the NLRP3 inflammasome in gout. J Inflamm Res 4: 39-49.
55. Martinon, F., V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp. 2006. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241. (Pubitemid 43372104)